Joana Santos

Joana Santos


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JSJoana Santos
Joana Santos
MCMiguel Gomes Cardoso
Miguel Gomes Cardoso
Irina MoreiraIrina Moreira
Irina Moreira
João GonçalvesJoão Gonçalves
João Gonçalves
João Domingos Galamba CorreiaJoão Domingos Galamba Correia
João Domingos Galamba Correia
Rita MeloRita Melo
Rita Melo
Biological therapies, such as recombinant proteins, are nowadays amongst the most promising approaches towards precision medicine. One of the most innovative methodologies currently available aimed at improving the production yield of recombinant proteins with minimization of costs relies on the combination of in silico studies to predict and deepen the understanding of the modified proteins with an experimental approach. The work described herein aims at the design and production of a biomimetic vector containing the single-chain variable domain fragment (scFv) of an anti-HER2 antibody fragment as a targeting motif fused with HIV gp41. Molecular modeling and docking studies were performed to develop the recombinant protein sequence. Subsequently, the DNA plasmid was produced and HEK-293T cells were transfected to evaluate the designed vector. The obtained results demonstrated that the plasmid construction is robust and can be expressed in the selected cell line. The multidisciplinary integrated in silico and experimental strategy adopted for the construction of a recombinant protein which can be used in HER2+-targeted therapy paves the way towards the production of other therapeutic proteins in a more cost-effective way.

19 November 2022 in Bioengineering
Verified
Journal Article
Open access
PDF file
SMSofia A. Martins
Sofia A. Martins
JSJoana Santos
Joana Santos
Sandra Cabo VerdeSandra Cabo Verde
Sandra Cabo Verde
João Domingos Galamba CorreiaJoão Domingos Galamba Correia
João Domingos Galamba Correia
Rita MeloRita Melo
Rita Melo
Virus-like particles (VLPs) are nanoplatforms comprised of one or more viral proteins with the capacity to self-assemble without viral genetic material. VLPs arise as promising nanoparticles (NPs) that can be exploited as vaccines, as drug delivery vehicles or as carriers of imaging agents. Engineered antibody constructs, namely single-chain variable fragments (scFv), have been explored as relevant molecules to direct NPs to their target. A vector containing the scFv of an antibody, aimed at the human epidermal growth factor receptor 2 (HER2) and fused to the human immunodeficiency virus (HIV) protein gp41, was previously constructed. The work herein describes the early results concerning the production and the characterization of HIV-1-based VLPs expressing this protein, which could function as potential non-toxic tools for transporting drugs and/or imaging agents.